Understanding Small Cell Lung Cancer: Stages, Treatment and Side Effects

Small cell lung cancer, or SCLC, is an aggressive type of lung cancer that grows and spreads quickly. It most often develops in the central airways of the lungs. SCLC is typically classified by stage, which describes the size of the tumor and whether it has spread to nearby lymph nodes or other organs. Early discussion with your oncologist about treatment options and potential side effects can help you make informed decisions throughout your care.

How small cell lung cancer is diagnosed

SCLC is diagnosed through a combination of imaging, biopsies and laboratory tests. Chest CT scans, PET scans and MRI may be used to assess the tumor and check for spread. A tissue biopsy confirms the diagnosis and provides information on how the cancer might respond to therapy. Your oncologist may also recommend additional tests to evaluate your overall health and lung function.

Treatment options for stage 1 small cell lung cancer

Stage 1 SCLC is confined to one area of the lung and has not spread to nearby lymph nodes. This early stage gives more treatment options, including surgery, and the goal is often curative.

1. Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce recurrence risk.
2. Second-line: If the cancer returns, chemotherapy or a combination of chemotherapy and immunotherapy may be recommended.
3. Third-line and beyond: Later lines of therapy may include different chemotherapy regimens or enrollment in clinical trials exploring new treatments.

Treatment options for stage 2 small cell lung cancer

Stage 2 SCLC has grown larger or may have spread to nearby lymph nodes but is still limited to the chest. Treatment usually involves a combination approach to target both the tumor and potential spread.

• Frontline: Chemotherapy combined with radiation therapy is typically recommended, with surgery in select cases.
• Second-line: Options may include different chemotherapy drugs, immunotherapy, or targeted therapy if eligible.
• Third-line and beyond: Clinical trials and palliative treatments may be discussed to manage symptoms and maintain quality of life.

Dr. Charles M. Rudin sat down for an interview with CURE to discuss recent treatment advancements for patients with small cell lung cancer, such as immunotherapies and T cell engagers including Imdelltra (tarlatamab).

“Within the last few years, there have been some changes in our standard of care that have really led to substantial benefits for patients,” Rudin said. “One has been the advent of immunotherapy. As it as for many cancers, the addition of immunotherapy to our chemotherapy backbone improves the probability of long-term benefit, and for some patients, offers truly transformative benefits. So that's been a major advance, really, over the last six or seven years.”

Treatment options for stage 3 small cell lung cancer

Stage 3 SCLC has spread more extensively within the chest, often involving multiple lymph nodes or nearby organs. This stage is usually treated with aggressive combined therapies.

• Frontline: Concurrent chemotherapy and radiation therapy are standard. In some cases, immunotherapy may be added after initial treatment.
• Second-line: Treatment may include different chemotherapy regimens, immunotherapy, or clinical trials.
• Third-line and beyond: Focus shifts to symptom management and maintaining quality of life, possibly including palliative radiation or supportive care.

Treatment options for metastatic small cell lung cancer

Metastatic SCLC has spread beyond the chest to distant organs such as the liver, brain or bones. Treatment focuses on controlling the disease, improving symptoms, and extending quality of life.

• Frontline: Combination chemotherapy and immunotherapy are often used to control the disease and improve symptoms.
• Second-line: Options include alternative chemotherapy regimens or participation in clinical trials.
• Third-line and beyond: Care focuses on symptom management and improving comfort, with supportive care teams providing guidance.

Common side effects of small cell lung cancer treatment

Treatment side effects vary depending on the therapy used. Common chemotherapy side effects include fatigue, nausea, hair loss, lowered blood counts and increased risk of infection. Radiation therapy can cause skin irritation, coughing or difficulty swallowing. Immunotherapy can trigger immune-related side effects such as skin rash, diarrhea or inflammation in organs. Your care team will monitor side effects closely and provide strategies to manage them.

Managing small cell lung cancer: what patients should know

SCLC is a fast-growing cancer, but understanding your diagnosis and treatment options can help you navigate care decisions. Ongoing communication with your oncologist is critical to choosing the right therapies, managing side effects and discussing clinical trials that may be appropriate. Support from nurses, social workers and patient resources can help you maintain quality of life throughout treatment.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.